SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
TCR2 Therapeutics Inc. (TCRR) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+237.8%).
- 分析师共识目标价 $5.00 (+237.8% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 42/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
估值概览 — TCRR
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-3.93
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$5.00 (+237.8%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$-1.93 |
$0.00 |
$-9.92M |
- |
| 2017 |
$-2.55 |
$0.00 |
$-13.07M |
- |
| 2018 |
$-1.05 |
$0.00 |
$-24.25M |
- |
| 2019 |
$-2.26 |
$0.00 |
$-47.6M |
- |
| 2020 |
$-2.40 |
$0.00 |
$-67.12M |
- |
| 2021 |
$-2.63 |
$0.00 |
$-99.81M |
- |
| 2022 |
$-3.93 |
$0.00 |
$-151.82M |
- |
